Alzamend Neuro Inc (ALZN) News

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a...

Form PRE 14A - Other preliminary proxy statements

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage...

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons...

Alzamend Neuro to Present at the Sequire Investor Summit

Company to report on progress with clinical trials to be initiated in 2025 and expected milestones Alzamend Neuro, Inc. (Nasdaq: ALZN...

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing...

Form 8-K - Current report

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million Stockholder equity of $3.8 million at...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and...

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety...

Form 8-K - Current report

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the...

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

Fireside conversation to take place on October 17, 2024, at 1:30 PM ET Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage...

Form 424B5 - Prospectus [Rule 424(b)(5)]